Determination of Susceptibility Rates of Nosocomial Acinetobacter baumannii Isolates to Sulbactam by E-test Method

Nozokomiyal Acinetobacter baumannii İzolatlarında Sulbaktam Duyarlılık Oranlarının E-test Yöntemi ile Belirlenmesi

Fatih TEMOÇİN¹, Necla TÜLEK², F. Şebnem ERDİNC², Şirin HEKİMOĞLU², Meryem DEMİRELLİ³, Günyay ERTEM², Hünerk ŞAHİN⁴, Cemal BULUT⁵, Çiğdem ATAMAN HATİPOĞLU², Sami KİNİKLİ²

1 Clinic of Infectious Diseases and Clinical Microbiology, Yozgat State Hospital, Yozgat, Turkey
2 Clinic of Infectious Diseases and Clinical Microbiology, Ankara Training and Research Hospital, Ankara, Turkey
3 Clinic of Infectious Diseases and Clinical Microbiology, Zonguldak Atatürk State Hospital, Zonguldak, Turkey
4 Department of Microbiology, Rize Public Health Laboratory, Rize, Turkey
5 Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, University of Kırıkkale, Kırıkkale, Turkey

SUMMARY

Introduction: Bacteria of the genus Acinetobacter play an important role as causative agents of hospital-acquired infections. Multidrug-resistant Acinetobacter infections have increasingly been observed worldwide. In parallel with the increasing rate of infections, therapeutic options are becoming limited. Although the susceptibility rates are not exactly known, sulbactam alone or sulbactam with ampicillin play a part in combination therapies against Acinetobacter infections. This study aimed to determine the minimum inhibitory concentrations (MICs) of sulbactam against multidrug-resistant Acinetobacter baumannii strains using the E-test method and to deduce the susceptibility rates based on literature data.

Materials and Methods: The study included 100 multidrug-resistant A. baumannii strains isolated from clinical samples obtained from patients hospitalized in intensive care units of the Ministry of Health Ankara Training and Research Hospital between June 15, 2011 and June 15, 2013. Antibiotic susceptibility testing and strain identification were performed using conventional methods and the VITEK 2 (bioMérieux SA, France) system. Resistance to three or more drugs was considered as multidrug resistance. MIC, MIC₅₀, and MIC₉₀ values (µg/mL) of sulbactam against the 100 isolates were determined using the E test method. Since the breakpoint MIC of sulbactam against Acinetobacter had not been established, the susceptibility rates were estimated based on the MIC values reported in the literature (≤ 4 or 8 µg/mL).

Results: The MIC values of sulbactam against the Acinetobacter isolates ranged widely (between 1 and 256 µg/mL), and the MIC₅₀ and MIC₉₀ values were determined to be 12 and 96 µg/mL, respectively. When 8 µg/mL was considered as the susceptibility breakpoint, 44% of the isolates were found to be susceptible; however, the rate was only 21% when 4 µg/mL was considered as the breakpoint.

Conclusion: Based on its MIC values determined in our study, sulbactam appeared to be a promising agent for the treatment of infections caused by multidrug-resistant A. baumannii isolates. Nonetheless, more studies are needed, especially on its clinical effectiveness.

Key Words: Sulbactam; Acinetobacter baumannii; E-test
INTRODUCTION

Bacteria of the genus Acinetobacter are important agents causing hospital-acquired infections[1]. High incidences of nosocomial infections caused by these pathogens are due to their tolerance of environmental conditions and ability to easily become resistant to antibiotics. Acinetobacter baumannii is a species commonly isolated from patients and hospital environments[2].

In recent years, Acinetobacter species have become resistant to antibiotics, especially to the use of broad-spectrum antibiotics increased. Particularly in intensive care units (ICUs), where invasive interventions (such as intubation and urinary or intravenous catheterization) are frequently performed, multidrug-resistant Acinetobacter infections are becoming increasingly more troublesome[3].

Due to the escalation of antimicrobial resistance among microorganisms, attempts have been made to develop new treatment protocols. Combination therapy, development of new antibiotics, and using obsolete antibiotics are just some examples of these studies.

Sulbactam is a semisynthetic compound with the chemical name penicillanic acid sulfone. It is a specific inhibitor of beta-lactamases produced by several gram-positive and gram-negative aerobic and anaerobic microorganisms. In particular, this drug inhibits chromosomal enzymes of Citrobacter.
In addition to beta-lactamase inhibition, sulbactam also has intrinsic bactericidal activity against some multidrug-resistant Acinetobacter species through penicillin-binding protein 2 \[^4,5\]. Sulbactam alone displays direct antimicrobial activity against Bacteroides fragilis and Acinetobacter species \[^7\]. The efficacy of sulbactam has been confirmed in several studies documenting successful treatments of Acinetobacter-related serious infections, including meningitis and ventriculitis. However, the incidence of resistance to sulbactam is also gradually increasing \[^6\].

In this study, minimum inhibitory concentrations (MICs) of sulbactam were determined against multidrug-resistant A. baumannii strains to investigate the potential of sulbactam as a treatment option.

**MATERIALS and METHODS**

This study was conducted at the Department of Infectious Diseases and Clinical Microbiology of the Ministry of Health Ankara Training and Research Hospital between June 15, 2011 and June 15, 2013. Our study included 100 multidrug-resistant (including carbapenem-resistant) A. baumannii isolates that were obtained from clinical samples sent to our microbiology laboratory from hospital ICUs. Isolates were collected over a 2 year period from different wards and different dates, and only one clinical isolate was included per patient. The 100 isolates were preserved at 80°C in the brain heart infusion broth (Oxoid, UK) containing glycerol.

For the study, the A. baumannii isolates were taken out of the deep freezer and subcultured on pre-cast EMB and sheep blood agar media. After 18-28 h of incubation in an aerobic atmosphere at 35 ± 2°C, bacterial colonies from fresh subcultures were used.

Bacterial suspensions equivalent to 0.5 McFarland turbidity standard were prepared for each isolate and evenly spread on Mueller-Hinton agar with sterile cotton swabs. The stored Etest strips (bioMerieux SA, France) were taken out of the 80°C freezer, allowed to stay at room temperature for 30 min, and then placed on the inoculated Mueller-Hinton agar plates. Plates were placed in an incubator and assessed after 18-24 hours. MIC values of the antibiotic tested were determined based on the point where the zone of complete growth inhibition intersected the Etest strip.

The MIC, MIC\(_{50}\), and MIC\(_{90}\) values (µg/mL) of sulbactam against the 100 isolates, which were determined with the Etest method, were recorded, and the susceptibility rates were deduced. None of the “Clinical and Laboratory Standards Institute (CLSI)”, “European Committee on Antimicrobial Susceptibility Testing (EUCAST)”, and “Food and Drug Administration (FDA)” guidelines provides the breakpoint MIC values for sulbactam alone. Therefore, the susceptibility rates were calculated based on the MIC limit values reported in the literature (≤ 4 and ≤ 8 µg/mL) \[^8\]. Moreover, estimations were done by taking as a reference sulbactam in the ampicillin-sulbactam combination provided in the CLSI guidelines, similar to other studies (Table 1) \[^9,10\]. Escherichia coli ATCC 25922 was used as a control strain.

**RESULTS**

We evaluated 100 A. baumannii isolates from clinical samples obtained from hospitalized patients. Most of the strains were isolated from tracheal-aspirate culture. The second was isolated from the urine culture and then the blood culture.
The sulbactam MIC ranges, MIC$_{50}$ and MIC$_{90}$ values (µg/mL), and the susceptibility rates (based on the MIC values provided in the CLSI guidelines for sulbactam in the ampicillin-sulbactam combination) for the isolates included in this study are shown in Table 2.

Depending on whether 4 or 8 µg/mL was used as the susceptibility breakpoint, 21 (21%) or 44 (44%) isolates were found to be susceptible to sulbactam, respectively.

**DISCUSSION**

In ICUs in Turkey, *Acinetobacter*-associated infections have become the most frequently observed and most difficult to treat infections$^{[11,12]}$. The Acinetobacter strains used in our study were also isolated from patients hospitalized in ICUs and included isolates resistant to carbapenem. The most frequent hospital-acquired infection in our ICUs is ventilator-associated pneumonia. Therefore, most of the strains used in this study were isolated from tracheal-aspirate culture. In this study depending on whether 4 or 8 µg/mL was used as the susceptibility breakpoint, 21 (21%) or 44 (44%) isolates were found to be susceptible to sulbactam, respectively.

Table 1. The limit of MIC values of *Acinetobacter baumannii* strains as suggested by CLSI

| Antimicrobial drug | Susceptible | Intermediate | Resistant |
|-------------------|-------------|--------------|-----------|
| Sulbactam*         | ≤ 4         | 8            | ≥ 16      |

MIC: Minimum inhibitory concentration, CLSI: Clinical and Laboratory Standards Institute.
*A range of MIC for sulbactam within ampicillin-sulbactam combination was used as indicated in CLSI guideline.

High rates of resistance to antibiotics in *A. baumannii* isolates lead to difficulties in the treatment of related infections and need for alternative therapeutic options. Due to the inefficiency of the current treatment, combined use of antibiotics was proposed. First studies demonstrating direct antimicrobial activity of sulbactam against *Acinetobacter* species were performed in the 1980s$^{[7,13]}$. It was also demonstrated that the efficacy of sulbactam against carbapenem-resistant *Acinetobacter* species was higher than that of colistin$^{[14]}$. Nonetheless, sulbactam alone is not recommended as a treatment option, and it is usually administered in combination treatments, namely, with ampicillin and cefoperazone. A combination of sulbactam and carbapenem was reported to show a high level of synergistic activity$^{[15]}$.

A limited number of studies have been conducted on the efficacy of sulbactam alone, with two of them being of most interest. Swenson et al. assessed 195 *A. baumannii* isolates by the microdilution method and determined MIC$_{50}$ and MIC$_{90}$ values for sulbactam to be 8 and 128 µg/mL, respectively$^{[16]}$. In a study by Hawley et al., which included 95 *A. baumannii* isolates, MIC$_{50}$ and MIC$_{90}$ values were determined to be 16 and 64 µg/mL, respectively, by the microdilution method$^{[17]}$. In our study, the MIC$_{50}$ and MIC$_{90}$ values were similarly found to be 12 and 96 µg/mL by using the Etest method. Due to the lack of an established susceptibility breakpoint in this study, similar to other studies, the resistance pattern could not be inferred.

The fact that there are no established breakpoint MIC values for sulbactam in the CLSI, EUCAST, and FDA guidelines makes interpretation of the test results difficult. Although direct bactericidal

Table 2. MIC range, MIC$_{50}$ and MIC$_{90}$ values, and rate of susceptibility of sulbactam against *Acinetobacter baumannii* isolates as determined with E-test

| Antibiotic | Bacteria (n=100) | MIC range (µg/mL) | MIC$_{50}$ (µg/mL) | MIC$_{90}$ (µg/mL) | Susceptible (%) | Intermediate (%) | Resistant (%) |
|------------|------------------|-------------------|-------------------|-------------------|----------------|-----------------|--------------|
| Sulbactam  | 100              | 1-256             | 12                | 96                | 21             | 38              | 41           |

MIC: Minimum inhibitory concentration, CLSI: Clinical and Laboratory Standards Institute.
*A range of MIC for sulbactam within ampicillin-sulbactam combination was used as indicated in CLSI guideline.
activity of sulbactam against A. baumannii is recognized, there are no specific data on an efficient therapeutic dose and correlation of MIC values with a clinical response. Therefore, the MIC ranges for sulbactam were determined using as a reference the sulbactam data in an ampicillin-sulbactam combination, provided in the CLSI guidelines, as done in similar studies. Consequently, it was determined that susceptible isolates constituted 21% (21/100), while 38% (38/100) were intermediate, and 41% (41/100) were resistant. When the MIC value of ≤8 µg/mL was used as a susceptibility breakpoint for sulbactam, 44% of the isolates were found to be susceptible. Despite the discrepancies between the numbers of isolates susceptible to sulbactam, the data confirm that some multidrug-resistant Acinetobacter strains are susceptible to sulbactam. Colistin is currently the only choice for carbapenem-resistant strain infections, and resistance to colistin is alarming. Beside these, side effects of colistin especially on renal functions are limiting the use of it. Therefore, sulbactam alone or in combination may be a today’s option to treat some infections caused by multidrug-resistant Acinetobacter strains. Consequently, we believe that sulbactam should be promoted in clinical studies to determine its MIC values for Acinetobacter species and the efficacy of single or combined administration.

The most important limitation of this study is that its results could not be applied to clinical practice due to the lack of established MIC values for sulbactam.

REFERENCES

1. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996;9:148-65.
2. Roberts SA, Findlay R, Lang SD. Investigation of an outbreak of multi-drug resistant Acinetobacter baumannii in an intensive care burns unit. J Hosp Infect 2001;48:228-32.
3. Bacakoglu F, Korkmaz Ekren P, Tosbakan MS, Basarik B, Pullukcu H, Aydemir S, et al. Multidrug-resistant Acinetobacter baumannii infection in respiratory intensive care unit. Mikrobiyol Bul 2009;43:575-85.
4. Akova M. Sulbaktam-Sefoperazon: In vitro çalışmalar ve klinik kullanımında yeni veriler. FLORA 2006;11(ssuppl 2).
5. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33.
6. Allen DH BJ, Acinetobacter species. In: Mandel GL BJ, Dolin R (eds), Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases: Churchill Livingstone, 2010:2881-5.
7. Frank U, Daeschner FD. In vitro activity of sulbactam plus ampicillin against hospital isolates of coagulase-negative staphylococci and Acinetobacter species. Infection 1989;17:272-4.
8. Oliveira MS, Costa SF, Pedri E, van der Heijden I, Levin AS. The minimal inhibitory concentration for sulbactam was not associated with the outcome of infections caused by carbapenem-resistant Acinetobacter spp. treated with ampicillin/sulbactam. Clinics (Sao Paulo) 2013;68:569-73.
9. The Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement; M100-S17. Zone Diameter Interpretive Standards and Equivalent Minimal Inhibitory Concentration (MIC) Breakpoint for Acinetobacter species (Table 2B-2). Wayne, Pa: The Clinical and Laboratory Standards Institute (CLSI) 2007; 27:40-1.
10. Henwood CJ, Gatward T, Warner M, James D, Stockdale MW, Spence RP, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002;49:479-87.
11. Ozdem B, Gurelik FC, Celikbilek N, Balikci H, Acikgoz ZC. Antibiotic resistance profiles of Acinetobacter species isolated from several clinical samples between 2007-2010. Mikrobiyol Bul 2011;45:526-34.
12. Summary data from National Hospital-Acquired Infections Surveillance Network (UHESA) report, 2013. Available from: http://www.saglik.gov.tr/tr/dosya/1-88693/h/uhesa-analiz-2013.pdf. [07.06.2014]
13. Kitzis MD, Goldstein FW, Labia R, Acajer F. Activity of sulbactam and clavulanic acid, alone and combined, on Acinetobacter calcoaceticus. Annales de Microbiologie 1983;134A:163-8.
14. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 2008;61:1369-75.
15. Turk Dagi H, Kus H, Arslan U, Tuncer I. In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and ceftazidime against carbapenem-resistant Acinetobacter baumannii isolates. Mikrobiyol Bul 2014;48:311-5.
16. Swenson JM, Killgore GE, Tenover FC. Antimicrobial susceptibility testing of Acinetobacter spp. by NCCLS broth
16. Rodrigues AC, Miro LD, Watanobe MA, Copertino RC, Lima FP, Ferreira ML, et al. Analysis of resistance among Acinetobacter baumannii isolates from burns, surgical, and non-surgical areas. J Clin Microbiol 2004;42:5102-8.
17. Hawley JS, Murray CK, Griffith ME, McElmeel ML, Fulcher LC, Hospenthal DR, et al. Susceptibility of Acinetobacter strains isolated from deployed U.S. military personnel. Antimicrob Agents Chemother 2007;51:376-8.
18. Oliveira MS, Costa SF, Pedri E, van der Heijden I, Levin AS. The minimal inhibitory concentration for sulbactam was not associated with the outcome of infections caused by carbapenem-resistant Acinetobacter spp. treated with ampicillin/sulbactam. Clinics 2013;68:569-73.
19. Temocin F, Erdinc S, Tulek N, Demirelli M, Bulut C, Ertem G. Incidence and risk factors for colistin-associated nephrotoxicity. Jpn J Infect Dis 2015;68:318-20.